Johnson & Johnson (NYSE:JNJ) Shares Purchased by Avantax Advisory Services Inc.

Avantax Advisory Services Inc. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 10.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 213,330 shares of the company's stock after acquiring an additional 19,529 shares during the period. Avantax Advisory Services Inc.'s holdings in Johnson & Johnson were worth $35,379,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Lantz Financial LLC grew its position in Johnson & Johnson by 3.3% during the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock valued at $1,986,000 after buying an additional 377 shares during the period. Sulzberger Capital Advisors Inc. bought a new position in Johnson & Johnson during the fourth quarter valued at $453,000. Joel Isaacson & Co. LLC increased its position in Johnson & Johnson by 3.5% during the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after acquiring an additional 2,526 shares during the last quarter. State of Wyoming grew its holdings in shares of Johnson & Johnson by 205,580.0% in the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after purchasing an additional 10,279 shares during the last quarter. Finally, Range Financial Group LLC grew its holdings in shares of Johnson & Johnson by 18.9% in the first quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock worth $2,635,000 after purchasing an additional 2,529 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research reports. Wall Street Zen lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Finally, Raymond James Financial dropped their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Nine research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Trading Down 0.7%

Shares of NYSE JNJ traded down $1.27 during trading on Friday, hitting $168.29. 6,199,690 shares of the company were exchanged, compared to its average volume of 8,375,731. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The company has a fifty day moving average price of $156.08 and a 200-day moving average price of $155.78. The firm has a market capitalization of $404.92 billion, a PE ratio of 18.00, a P/E/G ratio of 2.16 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. Johnson & Johnson's revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $2.82 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.09%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.